Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biotechnology company Genentech, GlycArt, a company wholly-owned by Roche, and Roche have signed a collaboration agreement, including a license from GlycArt to Genentech, for the joint development and commercialization of GlycArt's GA101 molecule.
Subscribe to our email newsletter
The companies will be developing GA101, a humanized anti-CD20 monoclonal antibody engineered to increase both direct- and immune-mediated target cell death, for the potential treatment of hematological malignancies and other oncology-related B-cell disorders such as non-Hodgkin’s lymphoma.
In association with this agreement, Genentech, Roche and GlycArt will share certain development costs and Genentech will record $105 million in R&D expense in its third quarter 2008 results. Genentech will receive commercialization rights in the US.
GA101 is currently in Phase I/II clinical trials for CD20-positive B-cell malignancies, such as non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. GlycArt and Roche plan to provide an update on Phase I data for GA101 in December 2008.
Hal Barron, senior vice president of development and chief medical officer at Genentech, said: “This collaboration with GlycArt and Roche for the GA101 molecule complements our existing research program and our focus on innovative compounds. We are pleased that through this program we may have the potential to offer a new option to treat patients with hematological malignancies.”